GNLB » Topics » Employees

These excerpts taken from the GNLB 10-K filed Mar 31, 2008.
Employees
 
As of December 31, 2007, Genelabs had approximately 76 full-time equivalent employees, of whom 58 were involved in research and development and 18 were in administration. Our employees are not represented by any collective bargaining agreements and we have never experienced a work stoppage due to a labor dispute.
 
On January 30, 2008, we announced the resignation of James A. D. Smith as President and Chief Executive Officer, effective January 29, 2008. We are currently searching for his replacement, and our Executive Chairman, Irene A. Chow, Ph.D., and our Chief Financial Officer, Frederick W. Driscoll, have assumed leadership responsibilities until a successor is appointed.
 
Item 1A.   Risk Factors.
 
There are a number of risk factors that should be considered by Genelabs’ shareholders and prospective investors. It is not possible to comprehensively address all risks that exist, but the following risks in particular should be considered, in addition to other information in this Annual Report on Form 10-K.
 
Employees


 



As of December 31, 2007, Genelabs had approximately
76 full-time equivalent employees, of whom 58 were involved
in research and development and 18 were in administration. Our
employees are not represented by any collective bargaining
agreements and we have never experienced a work stoppage due to
a labor dispute.


 



On January 30, 2008, we announced the resignation of James
A. D. Smith as President and Chief Executive Officer, effective
January 29, 2008. We are currently searching for his
replacement, and our Executive Chairman, Irene A.
Chow, Ph.D., and our Chief Financial Officer, Frederick W.
Driscoll, have assumed leadership responsibilities until a
successor is appointed.







 















Item 1A.  

Risk
Factors.



 



There are a number of risk factors that should be considered by
Genelabs’ shareholders and prospective investors. It is not
possible to comprehensively address all risks that exist, but
the following risks in particular should be considered, in
addition to other information in this Annual Report on
Form 10-K.


 




This excerpt taken from the GNLB 10-K filed Mar 22, 2007.
Employees
 
As of December 31, 2006, Genelabs had approximately 67 full-time equivalent employees, of whom 50 were involved in research and development and 17 were in administration. Our employees are not represented by any collective bargaining agreements, and we have never experienced a work stoppage due to a labor dispute.
 
Item 1A.   Risk Factors
 
There are a number of risk factors that should be considered by Genelabs’ shareholders and prospective investors. It is not possible to comprehensively address all risks that exist, but the following risks in particular should be considered, in addition to other information in this Annual Report on Form 10-K.
 
This excerpt taken from the GNLB 10-K filed Mar 31, 2006.
Employees
 
As of December 31, 2005, Genelabs and its subsidiaries had approximately 66 full-time equivalent employees, of whom 50 were involved in research and development and 16 were in administration. Our employees are not represented by any collective bargaining agreements, and we have never experienced a work stoppage due to a labor dispute.
 
Item 1A.   Risk Factors
 
There are a number of risk factors that should be considered by Genelabs’ shareholders and prospective investors. It is not possible to comprehensively address all risks that exist, but the following risks in particular should be considered, in addition to other information in this Annual Report on Form 10-K.
 
This excerpt taken from the GNLB 10-K filed Mar 11, 2005.

Employees

        As of December 31, 2004, Genelabs and its subsidiaries had 69 full-time equivalent employees, of whom 51 were involved in research and development and 18 were in administration. Our employees are not represented by any collective bargaining agreements, and we have never experienced a work stoppage due to a labor dispute.

13



RISK FACTORS

        There are a number of risk factors that should be considered by Genelabs' shareholders and prospective investors. It is not possible to comprehensively address all risks that exist, but the following risks in particular should be considered, in addition to other information in this Annual Report on Form 10-K.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki